Protara Therapeutics, Inc. Common Stock
TARAProtara Therapeutics, Inc. (TARA) is a biotechnology company focused on developing innovative therapies for cancer and rare diseases. It is dedicated to advancing treatments through its pipeline of novel drug candidates, with an emphasis on targeted and personalized medicine approaches.
Company News
Protara Therapeutics plans to raise approximately $75 million through a public offering of 13,043,479 common stock shares at $5.75 per share, with proceeds intended to fund clinical development of TARA-002 and other programs.
Protara Therapeutics plans to raise $75 million through a public offering of common stock and pre-funded warrants. The proceeds will fund clinical development of TARA-002 and other clinical programs, with J.P. Morgan, TD Cowen, and Piper Sandler acting as joint book-running managers.
Protara Therapeutics reported a Q2 2025 net loss of $15.0 million, with no revenue but continued progress in clinical trials for TARA-002 and IV Choline Chloride. The company maintains $145.6 million in cash reserves, projecting operational funding into mid-2027.
Protara Therapeutics announced positive interim results from its ongoing Phase 2 ADVANCED-2 trial of TARA-002, its investigational cell-based therapy, in patients with high-risk non-muscle invasive bladder cancer (NMIBC). The results showed high complete response rates and a favorable safety profile.
Protara Therapeutics reported positive interim results from its ADVANCED-2 trial of TARA-002 in non-muscle invasive bladder cancer (NMIBC) patients. The company also expects to begin a pivotal trial for IV Choline Chloride and report data from its STARBORN-1 trial of TARA-002 in lymphatic malformations in 2025.
